Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s share price gapped up before the market opened on Thursday . The stock had previously closed at $8.76, but opened at $9.03. Mesoblast shares last traded at $9.23, with a volume of 60,105 shares traded.
Analysts Set New Price Targets
A number of equities research analysts have recently commented on the stock. StockNews.com cut shares of Mesoblast from a "hold" rating to a "sell" rating in a report on Wednesday, September 4th. Jefferies Financial Group raised Mesoblast from a "hold" rating to a "buy" rating in a research report on Thursday, August 29th. Maxim Group raised Mesoblast from a "hold" rating to a "buy" rating and set a $12.00 target price on the stock in a report on Tuesday, September 24th. Cantor Fitzgerald restated an "overweight" rating on shares of Mesoblast in a research note on Thursday, August 29th. Finally, Piper Sandler raised shares of Mesoblast from a "neutral" rating to an "overweight" rating and boosted their price objective for the company from $4.00 to $11.00 in a research note on Tuesday, July 23rd. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $11.50.
Check Out Our Latest Analysis on MESO
Mesoblast Trading Up 9.0 %
The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21. The business has a 50 day moving average price of $6.63 and a 200-day moving average price of $6.59. The firm has a market capitalization of $1.09 billion, a PE ratio of -8.36 and a beta of 3.47.
Institutional Investors Weigh In On Mesoblast
Hedge funds and other institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC grew its holdings in Mesoblast by 50.1% in the second quarter. GAMMA Investing LLC now owns 4,981 shares of the company's stock valued at $34,000 after purchasing an additional 1,663 shares during the last quarter. Perkins Coie Trust Co purchased a new stake in shares of Mesoblast in the second quarter valued at about $68,000. Pine Valley Investments Ltd Liability Co acquired a new stake in shares of Mesoblast in the second quarter valued at approximately $80,000. Rathbones Group PLC purchased a new position in Mesoblast during the second quarter worth $95,000. Finally, Chapin Davis Inc. increased its position in Mesoblast by 50.0% during the 2nd quarter. Chapin Davis Inc. now owns 15,000 shares of the company's stock worth $102,000 after purchasing an additional 5,000 shares in the last quarter. Institutional investors and hedge funds own 1.43% of the company's stock.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Featured Articles
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
